Neoleukin Therapeutics (NLTX) News Today $15.33 -1.90 (-11.03%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Neoleukin Therapeutics (NASDAQ:NLTX) Shares Down 0.8% Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 0.8%March 14, 2024 | marketbeat.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comNeurogene, Neoleukin Announce Planned MergerJuly 19, 2023 | markets.businessinsider.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | msn.comNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | markets.businessinsider.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | msn.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | marketwatch.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | technews.tmcnet.comNeurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 23, 2023 | finance.yahoo.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)May 9, 2023 | markets.businessinsider.comNeoleukin Therapeutics promotes general counsel to interim CEOApril 7, 2023 | bizjournals.comNLTX Neoleukin Therapeutics, Inc.March 31, 2023 | seekingalpha.comNeoleukin Therapeutics (NLTX) Receives a Hold from Mizuho SecuritiesMarch 21, 2023 | markets.businessinsider.comHere's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationMarch 10, 2023 | finance.yahoo.comSeattle biotech company CEO steps down amid steep job cutsMarch 10, 2023 | bizjournals.comNeoleukin Therapeutics Shares Climb 29% on 70% Workforce Reduction, Strategic AlternativesMarch 9, 2023 | marketwatch.comShares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or mergerMarch 9, 2023 | msn.comNeoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 MonthsMarch 9, 2023 | finance.yahoo.comNeoleukin Therapeutics to cut 70% workforce, CEO steps downMarch 9, 2023 | msn.comNeoleukin Therapeutics Eyes Strategic Alternatives, Will Cut StaffMarch 8, 2023 | marketwatch.comMizuho Securities Keeps Their Hold Rating on Neoleukin Therapeutics (NLTX)March 8, 2023 | markets.businessinsider.comNeoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionMarch 8, 2023 | finance.yahoo.comNeoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual MeetingDecember 12, 2022 | finance.yahoo.comNeoleukin (NLTX) Stops Development of Lead Drug, Stock DownNovember 16, 2022 | finance.yahoo.comMizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a HoldNovember 15, 2022 | markets.businessinsider.comNeoleukin Pauses Development Of NL-201, Cuts 40% Of Employee StrengthNovember 15, 2022 | finance.yahoo.comNeoleukin cut to Hold at Stifel on plans to drop lead assetNovember 15, 2022 | seekingalpha.com5 Analysts Have This to Say About Neoleukin TherapeuticsNovember 15, 2022 | markets.businessinsider.comNeoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdateNovember 15, 2022 | finance.yahoo.comTrading was temporarily halted for "NLTX" at 04:11 PM with a stated reason of "News pending."November 14, 2022 | marketbeat.comNeoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual MeetingNovember 3, 2022 | finance.yahoo.comWe're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateOctober 1, 2022 | finance.yahoo.comNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 10, 2022 | seekingalpha.comRecap: Neoleukin Therapeutics Q2 EarningsAugust 9, 2022 | msn.com Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. NLTX Media Mentions By Week NLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLTX News Sentiment▼0.000.47▲Average Medical News Sentiment NLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLTX Articles This Week▼00▲NLTX Articles Average Week Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XBiotech News Annexon News VectivBio News Humacyte News ABIVAX Société Anonyme News Astria Therapeutics News Sana Biotechnology News Monte Rosa Therapeutics News Organogenesis News PureTech Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
